Wed Sep 25 09:25:48 UTC 2024: ## Gabelli Funds Increases Stake in Novo Nordisk
**New York, NY** – Gabelli Funds LLC has increased its stake in Novo Nordisk A/S (NYSE:NVO) by a significant 35.7% during the second quarter, according to the firm’s latest 13F filing with the SEC. This move reflects a growing confidence in the Danish pharmaceutical giant’s performance, with Gabelli Funds now holding 46,963 shares of Novo Nordisk.
The increased investment follows a strong performance from Novo Nordisk in the first half of 2023, driven by robust sales of its flagship diabetes and obesity treatments. Analysts believe that the company’s expanding portfolio of innovative drugs, including the highly anticipated Wegovy weight-loss medication, positions it for continued growth in the coming years.
Gabelli Funds’ decision to boost its stake in Novo Nordisk underscores the growing optimism surrounding the pharmaceutical company’s future prospects. The firm’s significant investment is expected to further fuel the company’s expansion and innovation efforts, potentially leading to even stronger financial performance in the near future.
First Piper 